154.14 0.00 (0.00%)
After hours: 5:35PM EDT
|Bid||146.45 x 900|
|Ask||155.00 x 1100|
|Day's Range||153.38 - 158.51|
|52 Week Range||97.65 - 159.54|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||127.39|
|Earnings Date||Jul 22, 2019 - Jul 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.72|
Disruptive tech simplifies patient engagement and amplifies patients’ voices to advance outcomes for life science companies
Summer is here (June 21 is the first day of summer solstice). You might be tempted to ditch the stock market and take the next three months off. But you if you do, you'll miss some sizzling summer-stock action.
IQVIA™ (IQV) today announced that Chiesi Farmaceutici, the international research-focused healthcare Group (Chiesi Group) is leveraging IQVIA Technologies’ Orchestrated Customer Engagement (OCE) technology platform to enhance customer proximity and teamwork effectiveness in more than 20 markets, including the U.S., China, Germany, U.K., France, Spain, Italy, Russia and Brazil.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]
Italian multinational pharmaceutical company to coordinate all physical and digital activities with pharmacists using IQVIA Technologies’ end-to-end solution. IQVIA™ (IQV) today announced that Zambon, an Italian multinational pharmaceutical and fine-chemical company, has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ transformative commercial engagement technology, to maximize customer interactions and to make a real impact within the retail channel.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Previously announced FDA approval of IBRANCE® for the treatment of men with metastatic breast cancer based in part on IQVIA real world analytics; Pfizer Oncology to p
The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications, that in 2018 a record-setting 15 new active substance (NAS) oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S. Those 2018 debuts bring the total number of new oncology therapeutics launched since 2013 to 57 covering 89 approved indications for 23 different tumor types.
IQVIA™ (IQV) today announced that three of the company’s women leaders have received significant awards for their leadership, vision and strategic abilities to drive disruptive technologies, improve health outcomes, and advance innovation. Deepa Desai, MD, IQVIA’s vice president, Quality Assurance, was awarded the 2019 Healthcare Businesswomen’s Association HBA Luminary Award. Marla Kessler, IQVIA’s senior vice president, Strategy, Marketing & Communications, has been named to MM&M magazine’s annual Hall of Femme list.
Stock investors looking for a way to outperform amid the trade war's major upheaval should look at Goldman Sachs' Hedge Funds VIP list.
IQVIA Holdings Inc. , announced today that Ari Bousbib, chairman and chief executive officer, will speak at the William Blair 39th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 5, 2019 at 10:40 a.m.
IQVIA Holdings Inc. , will host an Analyst and Investor Conference in New York City on Tuesday, June 18, 2019. Management will provide an update on the business, with presentations starting at 9:00 a.m.
IQVIA MedTech provides innovative technology, focused solutions and consulting services to meet the industry-specific needs of this life sciences segment from concept-to-market
On Monday, Beijing made it very clear — almost 5,000 U.S. products will face as high as 25 percent increase in tariffs.
Spending on all U.S. medicines increased 4.5 percent to $344 billion on a net price basis, despite lower price growth, due to higher patient use of new and protected brands. In 2018, 29 billion fewer morphine milligram equivalents (MMEs) were dispensed to patients on a volume basis compared to 2017. The steepest decline occurred in the “high-strength” formulations ( =90 MMEs/day), which declined by 61 percent since 2011.
Prescription opioid use in the U.S. was down 17% in 2018, marking the largest annual decline ever recorded, a study by research firm IQVIA Institute for Human Data Science finds.
IQVIA Holdings Inc. (“IQVIA”) (IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,100,000,000 in aggregate principal amount of senior notes due 2027 (the “notes”). The net proceeds from the notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility, to pay fees and expenses related to the notes offering and for other general corporate purposes.